Bal Pharma Limited has notified the stock exchanges of the resignation of Mr. Abdul Basith (Membership No. A70640) from the position of Company Secretary & Compliance Officer of the company, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The resignation takes effect from the close of business hours on Monday, May 11, 2026, and was formally accepted on the same date.

Resignation Details

Mr. Abdul Basith had submitted his resignation letter on March 2, 2026, citing his decision to pursue an alternate career opportunity outside the organisation. In accordance with the company's HR policy, he had requested to be relieved of his responsibilities effective 60 days from the date of the resignation letter. The company accepted the resignation on May 11, 2026, marking the conclusion of his tenure as Company Secretary, Compliance Officer, and Deputy Nodal Officer (IEPF) of Bal Pharma Limited.

The key details of the resignation, as disclosed under the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, are as follows:

Interim Communication Arrangements

Bal Pharma Limited has informed the exchanges that until a formal announcement is made regarding the appointment of a new Company Secretary & Compliance Officer, all communications relating to the company should be directed to secretarial@balpharma.com . The intimation was signed by Shailesh Siroya, Managing Director of Bal Pharma Limited, on May 12, 2026.

The company has also indicated that the necessary statutory filings, including the relevant forms with the Registrar of Companies under the Ministry of Corporate Affairs, will be completed to give effect to the resignation.

Bal pharma Limited has filed its mandatory regulatory confirmation with stock exchanges regarding compliance with SEBI (Depository Participant) Regulations for the quarter ended March 31, 2026. The pharmaceutical company submitted the confirmation as required under Regulation 74(5) of SEBI (DP) Regulations.

Regulatory Compliance Confirmation

The company confirmed that all details of securities dematerialized and rematerialized during the quarter ended March 31, 2026, have been furnished to stock exchanges where its equity shares are listed. This submission was completed within the prescribed time limits as mandated by regulatory requirements.

Certificate Processing Details

Bal Pharma Limited confirmed that share certificates received for dematerialization have been properly processed according to regulatory standards. The company stated that certificates were mutilated and cancelled after due verification, with the depository's name substituted in records as the registered owner within 15 days of certificate receipt.

Communication and Authorization

The confirmation was digitally signed by Shailesh Siroya, serving as the authorized signatory for Bal Pharma Limited. The communication was addressed to both National Stock Exchange of India Limited and BSE Limited in Mumbai, with copies sent to National Securities Depository Limited and Central Depository Services (India) Limited.

The confirmation was dated April 6, 2026, and sent from the company's corporate office located at 5th Floor, H. M. Narayan Complex, Palace Road, Bangalore. This regulatory filing demonstrates the company's adherence to SEBI's depository participant regulations and maintains transparency with stock exchanges and depositories.